公开(公告)号：AU2011296085A1

公开(公告)日：2013-03-28

申请号：AU2011296085

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

IPC: C12P21/06

Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.

公开(公告)号：CA2981883A1

公开(公告)日：2016-10-20

申请号：CA2981883

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：CA2809677A1

公开(公告)日：2012-03-08

申请号：CA2809677

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

IPC: C07K16/30 ,  A61K9/14 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K17/02 ,  C12N15/13 ,  G01N33/574

Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.

公开(公告)号：AU2016249991A1

公开(公告)日：2017-10-12

申请号：AU2016249991

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：SG188324A1

公开(公告)日：2013-04-30

申请号：SG2013014832

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

Abstract: Title: ANTI-C-MET ANTIBODY AND METHODS OF USE THEREOF Abstract:

公开(公告)号：AU2016249991B2

公开(公告)日：2021-03-25

申请号：AU2016249991

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：SG11201707949XA

公开(公告)日：2017-10-30

申请号：SG11201707949X

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：ES2882276T3

公开(公告)日：2021-12-01

申请号：ES16780542

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28 ,  A61K31/33 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02 ,  C07K16/30 ,  C12N15/11

Abstract: Un anticuerpo o un fragmento de unión a antígeno del mismo que tiene una afinidad de unión específica a un epítope que se encuentra dentro del dominio 3 del receptor 2 del factor de crecimiento endotelial vascular humano (VEGFR2; SEQ ID NO: 74), en donde el epítope dentro del dominio 3 del VEGFR2 se encuentra entre los residuos de aminoácidos 250 y 270 de SEQ ID NO: 74, y además en donde el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), la VH comprende VH CDR1, VH CDR2 y VH CDR3 y la VL comprende VL CDR1, VL CDR2 y VL CDR3, en donde: la VH CDR1, VH CDR2 y VH CDR3 comprenden la secuencia de aminoácidos de SEQ ID NO: 6, SEQ ID NO: 7 y SEQ ID NO: 8, respectivamente; y la VL CDR1, VL CDR2 y VL CDR3 comprenden la secuencia de aminoácidos de SEQ ID NO: 9, Asp Ala Ser y SEQ ID NO: 73, respectivamente.

公开(公告)号：CA2981883C

公开(公告)日：2019-10-22

申请号：CA2981883

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：BR112013004926A2

公开(公告)日：2016-07-05

申请号：BR112013004926

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  CHI MING LIANG

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

IPC: C12P21/06

Abstract: anticorpo anti-c-met e métodos para utilização do mesmo. os anticorpos que ligam a c-met são fornecidos aqui, bem como composições relacionadasl e métodos do uso. os métodos do uso abrangem a terapia de câncer e a diagnóstica. em certas modalidades, os anticorpos ligam o antígeno de superfície celular mamífero (p.ex., o antígeno de superfície celulars cancerosas). os anticorpos também podem ser endocitados para ligar a células. o que de células pode ser visado pelos anticorpos incluem carcinomas, tais como aqueles em pulmão, rim, fígado, estômago, peito, e cérebro, etc.